Skip to main content
SpringerLink
Log in

Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin

  • Lipids
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

The efficacy of simvastatin in reducing plasma cholesterol is well documented. Other molecules within the apo lipoprotein family, particularly lipoprotein (a) Lp(a), have recently been found to have a predictive and/or causative role in atherosclerosis. Based on these considerations, we studied 15 patients affected by primary hypercholesterolemia to evaluate the effect of simvastatin in Lp(a) and apoprotein plasma levels (A1, B, C2, C3, E), in addition to the classic lipid parameters. Clinical and laboratory parameters were evaluated before therapy, after 12 weeks of therapy, and after 5 weeks of drug withdrawal. Simvastatin therapy produced a significant reduction in total cholesterol (CH) and LDL-CH (p<0.0001), and a significant increase in HDL-CH (p<0.01); no variation was observed in triglyceride (TG) levels. Simvastatin therapy further showed a significant decrease in apoC2 (p<0.05), the apo C2/C3 ratio (p<0.01), and apoE (p<0.01), as well as a significant increase in Lp(a) plasma levels (p<0.05). All of the parameters studied returned to pretreatment values 5 weeks after drug withdrawal; only HDL-CH persisted above the values reached during therapy. Our data agree with those documenting the beneficial effect of simvastatin in greatly decreasing CH and LDL-CH, but point out the need for further studies on the long-term effect of simvastatin on apoprotein molecules, such as on Lp(a), in order to fully establish its role in the secondary prevention of atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kannel WB, Castelli WP, Gordon T. Lipoprotein cholesterol in the prediction of atherosclerotic disease: New perspectives based on the Framingham Heart Study.Ann Intern Med 1979;90:85–91.

    PubMed  Google Scholar 

  2. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Heart Study.JAMA 1986;256:2835–2838.

    PubMed  Google Scholar 

  3. Consensus Conference. Lowering blood cholesterol to prevent heart disease.JAMA 1985;253:2080–2086.

    Google Scholar 

  4. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial result. I. Reduction in incidence of coronary heart disease.JAMA 1984;251:351–364.

    Google Scholar 

  5. Gurewich V, Mittleman M. Lipoprotein(a) in coronary heart disease. Is it a risk factor after all?JAMA 1994;271:1025–1026.

    PubMed  Google Scholar 

  6. Grundy SM. HMGCo A reductase inhibitors for treatment of hypercholesterolemia.N Engl J Med 1988;319:24–32.

    PubMed  Google Scholar 

  7. Mertz B. Lp(a) joins other serum cholesterol lipoproteins as a risk determinant.JAMA 1989;261:2013–2014.

    PubMed  Google Scholar 

  8. Ito H, Nalto C, Hayashi H, Kawamura M. Activity of low-density lipoprotein receptors as estimated from concentrations of apolipoprotein B and C-II in serum.Clin Chem 1988;34:11:2224–2227.

    PubMed  Google Scholar 

  9. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).JAMA 1993;269:3015–3023.

    Google Scholar 

  10. Lipid Research Clinic Program.Manual of Laboratory Operations, vol. 1, Lipid and Lipoprotein Analysis. Department of Health, Education and Welfare (National Institutes of Health) publication no. 75-628, Washington, DC: US Government Printing Office, 1974.

    Google Scholar 

  11. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.Clin Chem 1972;18:499–502.

    PubMed  Google Scholar 

  12. Molgaard J, von Schenck H, Olsson AG. Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolemia.Eur Heart J 1988;9:541–551.

    PubMed  Google Scholar 

  13. Mol MJTM, Erkelens DW, Gevers Leuven JA, Schouten JA, Stalenhoef AFH. Simvastatin (MK-733): A potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolemia.Atherosclerosis 1988;69:131–137.

    PubMed  Google Scholar 

  14. Mol MJTM, Erkelens DW, Gevers Leuven JA, Schouten JA, Stalenhoef AFH. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolemia.Lancet 1986;2:936–939.

    PubMed  Google Scholar 

  15. Bard IM, Luc G, Douste-Blazy P, et al. Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolemia.Eur J Clin Pharmacol 1989;37:545–550.

    PubMed  Google Scholar 

  16. Kazumi T, Yoshino G, Okutani T, et al. Effects of simvastatin on plasma lipoproteins and apolipoproteins in Japanese diabetics with hypercholesterolemia. Abstract presented at the 8th International Symposium on Atherosclerosis, Rome, 9–13 October, 1988.

  17. Giudici GA, Stefanoni P, Cuchel M, Cerri MA, Clerichi MG. Effects of simvastatin on total and lipoprotein lipid, apoproteins and plasma Vitamin E in heterozygous familial hypercholesterolemia. Abstract presented at the 8th International Symposium on Atherosclerosis, Rome, 9–13 October, 1988.

  18. Bard JM, Parra HJ, Camare R, et al. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia with particular emphasis on lipoproteins defined by their apolipoprotein composition.Metabolism 1992;41:498–503.

    PubMed  Google Scholar 

  19. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction.JAMA 1986;256:2540–2544.

    PubMed  Google Scholar 

  20. Armstrong VW, Cremer P, Eberle E, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis.Atherosclerosis 1986;62:249–257.

    PubMed  Google Scholar 

  21. Slunga L, Johnson O, Dahlen GH. Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolemia with simvastatin.Eur J Clin Pharmacol 1993;43:363–373.

    Google Scholar 

  22. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a).Science 1993;260:1655–1658.

    PubMed  Google Scholar 

  23. Utermann G. The mysteries of lipoprotein(a).Science 1989;246:904–910.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CNR Institute of Clinical Physiology, Via Savi, 8, 56100, Pisa, Italy

    T. Sampietro M.D.

  2. Institute of 2th Medical Clinic University of Pisa, Pisa, Italy

    F. Galetta & A. Bionda

Authors
  1. T. Sampietro M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Galetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Bionda
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sampietro, T., Galetta, F. & Bionda, A. Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin. Cardiovasc Drug Ther 9, 785–789 (1995). https://doi.org/10.1007/BF00879872

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00879872

Key Words

Search

Navigation